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Previewsmicrofluidic devices for HTS could
include functional genomics and the
screening of genomic libraries for the
discovery of new enzymatic activities.
Such approaches will likely lead to better
exploitation of the immense potential in-
herent in the engineering of existing and
newly discovered enzymes for research
and biotechnological applications.
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Peptides perform a wide number of physiological roles as signaling molecules between cells as well as other
functions. The detection of peptides has generally relied on one of two distinct techniques: immunohisto-
chemistry and mass spectrometry. In this issue of Chemistry & Biology, Neupert and colleagues describe
an approach to combine these techniques.Peptides represent the largest group of
intercellular signaling molecules (Strand,
2003; Fricker, 2012). Well known exam-
ples include insulin (a peptide hormone)
and enkephalin (a neuropeptide). Hun-
dreds of distinct endogenous peptides
have been identified over the past
century, with recent advances in mass
spectrometry adding many additional
peptides in the past decade. Physiolog-
ical processes known to be controlled
by peptides include feeding and body
weight regulation, water intake, fertility,
arousal and sleep/wake cycles, thermo-
regulation, memory, pain, anxiety, and
depression (Strand, 2003; Fricker, 2012).
In addition to their role in cell-cell commu-
nication, peptides have been proposed to
play roles in intracellular signaling (Ferro
et al., 2004; Fricker, 2010).
Neuropeptides are produced from
precursor proteins by selective enzymesthat cleave the protein at specific sites
(Fricker, 2012). A number of examples
are known in which the precursor is
cleaved into different products depending
on the cell type, and these products have
distinct functions (Figure 1). For example,
the peptide adrenocorticotropic hormone
is the major product of its precursor in
mammalian anterior pituitary. While in
the intermediate pituitary, this peptide is
further cleaved into two smaller peptides:
alpha-melanocyte-stimulating hormone
and corticotropin-like intermediate lobe
peptide (Eipper et al., 1986). The different
sets of peptides derived from the same
precursor produce distinct physiological
effects, largely through binding to recep-
tors that are selective for either the larger
or smaller forms of each peptide. In
another example, the 31 amino acid-long
form of beta-endorphin is an agonist at
the mu opioid receptor, whereas the 27residue peptide is an antagonist at this
receptor (Hammonds et al., 1984). Thus,
in order to fully understand the function
of a neuron, it is not enough to know
what neuropeptide precursor the cell
expresses—it is necessary to know the
precise forms of peptides produced
within that neuron.
For decades, the major technique to
detect neuropeptides in individual cells
required antibodies to the peptide. Immu-
nohistochemical staining is very useful for
the localization of peptides to specific
cells in tissues. However, most antibodies
are not highly specific for just one form of
a peptide and often cross react with N-
and/or C-terminally extended peptides.
Furthermore, antibodies require prior
knowledge of the peptide and cannot be
used to detect novel peptides. Mass
spectrometry-based techniques have
emerged as powerful tools to characterizeª2012 Elsevier Ltd All rights reserved 931
Figure 1. Differential Processing of Neuropeptide Precursors in Distinct Cell Types
Most neuropeptides are produced from proteins that encode multiple bioactive peptides. The precursors
are cleaved at specific sites by a series of endopeptidases (proprotein convertases) and carboxypepti-
dases to generate the mature forms of the peptides. For some peptides, additional processing enzymes
are required to produce the bioactive forms. Due to differences in the enzyme composition between cells,
the precursors can be cleaved into distinct sets of peptides in various cell types. While antibodies often
cross react with larger and smaller forms of a peptide, mass spectrometry can detect the precise form
present in a biological sample.
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and can readily detect novel peptides
(Hummon et al., 2006). Recently, mass
spectrometry approaches have increased
their sensitivity to allow samples as small
as a single cell to be used, although
isolating the specific cell of interest has
remained problematic (Rubakhin et al.,
2011). Most previous attempts to use
mass spectrometry-based techniques
on cells probed with antibodies have
been hindered by the fixation step per-
formed as part of the immunohistochem-
ical staining. For example, fixation with
paraformaldehyde creates large cross-
linked molecules that interfere with the
ionization processes required for mass
spectrometry. In addition, paraformalde-
hyde reacts with peptides to form Schiff-
bases, altering the peptide’s mass. In932 Chemistry & Biology 19, August 24, 2012this issue ofChemistry & Biology, Neupert
et al. (2012) have solved these problems
by including a heating step in the pres-
ence of chemical reagents that reverse
the paraformaldehyde cross-linking, thus
freeing the bound peptide for subsequent
mass spectrometry measurements.
There are many potential applications
for this technique. By first probing a tissue
with antibodies, the cell type can be iden-
tified and subsequent mass spectrometry
analysis can identify the peptide compo-
nents of that cell. Neupert et al. (2012)
demonstrate this application by using
cells from the American cockroach (Peri-
planeta americana). With appropriate
refinement of the mass spectrometry
approaches, it should be possible to per-
form this analysis on mammalian tissues.
Other sample preparation approachesª2012 Elsevier Ltd All rights reservedcan be combined with these new proto-
cols to collect immunostained cells,
including flow cytometry and laser
capture microdissection. The combi-
nation of immunohistochemical-enabled
cell identification and single cell mass
spectrometry will provide more infor-
mation than either technique alone and
will contribute to a better understand-
ing of the molecular differences among
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Activation/exploitation of biosynthetic pathways for useful metabolites is a major current interest. The
metabolism remodeling approach developed by Craney and colleagues in this issue of (Chemistry & Biology),
in which small molecule probes alter the secondary metabolites produced by streptomycetes, could lead to
discovery of a multitude of novel antibiotics and other drugs.An important observation that emerged
from Streptomyces genome sequencing
projects was that although each straincontains genes that encode 20 or more
potential secondary metabolites, only
a fraction are expressed during fermenta-tion. Such cryptic biosynthetic pathways
promise to deliver a multitude of novel
bioactive compounds with the potential
